Ocular Therapeutix Approves Key Amendments at Annual Meeting

The latest announcement is out from Ocular Therapeutix ( (OCUL) ).

On June 11, 2025, Ocular Therapeutix held its Annual Meeting of Stockholders, where several key amendments were approved. These included increasing shares under the 2021 Stock Incentive Plan and the 2014 Employee Stock Purchase Plan, as well as updating the company’s Certificate of Incorporation to include officer exculpation. Additionally, the company completed enrollment for its SOL-R Phase 3 clinical trial for AXPAXLI, a treatment for wet AMD, on May 31, 2025, ensuring sufficient subjects for its target randomization.

The most recent analyst rating on (OCUL) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Ocular Therapeutix stock, see the OCUL Stock Forecast page.

Spark’s Take on OCUL Stock

According to Spark, TipRanks’ AI Analyst, OCUL is a Neutral.

Ocular Therapeutix’s stock score is primarily driven by financial performance challenges and valuation concerns due to negative profitability. Despite strong revenue growth, high operational losses and reliance on external funding are significant risks. Technical indicators show some positive momentum, but caution is advised due to proximity to long-term moving averages.

To see Spark’s full report on OCUL stock, click here.

More about Ocular Therapeutix

Ocular Therapeutix, Inc. operates in the pharmaceutical industry, focusing on developing innovative therapies for eye diseases. The company is known for its drug delivery platforms and products targeting ophthalmic conditions, with a market focus on treatments for conditions like wet age-related macular degeneration (AMD).

Average Trading Volume: 1,787,675

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.42B

For a thorough assessment of OCUL stock, go to TipRanks’ Stock Analysis page.